"Leukemia, Myeloid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
    
			
			
				
				
					
						| Descriptor ID | D007951 | 
					
						| MeSH Number(s) | C04.557.337.539 | 
					
						| Concept/Terms | Leukemia, MyeloidLeukemia, MyeloidLeukemia, GranulocyticMyeloid LeukemiaLeukemias, MyeloidMyeloid LeukemiasLeukemia, MyelogenousLeukemias, MyelogenousMyelogenous LeukemiasMyelocytic LeukemiaMyelogenous LeukemiaGranulocytic LeukemiaGranulocytic LeukemiasLeukemias, GranulocyticLeukemia, MyelocyticLeukemias, MyelocyticMyelocytic Leukemias
 Leukemia, Monocytic, ChronicLeukemia, Monocytic, ChronicMonocytic Leukemia, ChronicChronic Monocytic LeukemiaChronic Monocytic LeukemiasLeukemia, Chronic MonocyticLeukemias, Chronic MonocyticMonocytic Leukemias, Chronic
 | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid".
				
					
						- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Leukemia, Myelomonocytic, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Sarcoma, Myeloid
 
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Leukemia, Myeloid" by people in this website by year, and whether "Leukemia, Myeloid" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 1995 | 2 | 1 | 3 | 
| 1996 | 2 | 0 | 2 | 
| 1997 | 3 | 0 | 3 | 
| 1998 | 2 | 1 | 3 | 
| 1999 | 2 | 0 | 2 | 
| 2000 | 1 | 1 | 2 | 
| 2001 | 1 | 1 | 2 | 
| 2002 | 2 | 0 | 2 | 
| 2003 | 1 | 0 | 1 | 
| 2005 | 0 | 1 | 1 | 
| 2006 | 2 | 1 | 3 | 
| 2007 | 2 | 0 | 2 | 
| 2008 | 0 | 1 | 1 | 
| 2009 | 1 | 0 | 1 | 
| 2011 | 1 | 0 | 1 | 
| 2013 | 2 | 0 | 2 | 
| 2014 | 3 | 1 | 4 | 
| 2015 | 1 | 1 | 2 | 
| 2016 | 1 | 0 | 1 | 
| 2018 | 1 | 0 | 1 | 
| 2019 | 1 | 0 | 1 | 
| 2020 | 1 | 1 | 2 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Leukemia, Myeloid" by people in Profiles.
						
					
								- 
								What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia. Leukemia. 2023 11; 37(11):2324-2325. 
- 
								Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022 10 28; 12(10):144. 
- 
								Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond. Curr Hematol Malig Rep. 2021 06; 16(3):286-303. 
- 
								Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021 05 03; 218(5). 
- 
								EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021 03 22; 11(3):64. 
- 
								Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020 11; 52(11):1219-1226. 
- 
								HHEX promotes myeloid transformation in cooperation with mutant ASXL1. Blood. 2020 10 01; 136(14):1670-1684. 
- 
								Activating somatic and germline TERT promoter variants in myeloid malignancies. Leukemia. 2021 01; 35(1):274-278. 
- 
								Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397. 
- 
								Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020 02 15; 126(4):765-774.